deaths (OS)

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus docetaxel plus ADT
darolutamide plus doxetaxel plus ADT vs. docetaxel plus ADT 1 certainty unassessablestatistically conclusive-29%